-+ 0.00%
-+ 0.00%
-+ 0.00%

HiCisco (002653.SZ) obtains clinical trial approval for innovative drug HSK51155 tablets

Zhitongcaijing·08/18/2026 12:09:02
Listen to the news

Zhitong Finance App News, HiCisco (002653.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. After review, the clinical trial application for HSK51155 tablets accepted in June 2026 met the relevant requirements for drug registration and agreed to carry out clinical trials with this product. HSK51155 is an oral small molecule analgesic with independent intellectual property rights independently researched by the company. It is clinically intended for pain-related treatment.

In April 2026, the company reached a cooperation agreement with AbbVie Group Holdings Ltd. (hereinafter referred to as “AbbVie”) on hSK51155 and other related projects, granting AbbVie exclusive rights to develop, produce and commercialize on a global scale other than mainland China, the Hong Kong Special Administrative Region and the Macau Special Administrative Region. The total potential transaction amount exceeds US$700 million.